Journal of NeuroVirology

, Volume 12, Issue 5, pp 403–406 | Cite as

Valproic acid does not affect markers of human immunodeficiency virus disease progression

  • Beau M. Ances
  • Scott Letendre
  • Maria Buzzell
  • Jennifer Marquie-Beck
  • Deborah Lazaretto
  • Thomas D. Marcotte
  • Igor Grant
  • Ronald J. Ellis
  • HNRC Group
Short Communication

Abstract

Valproic acid (VPA) reduces latent human immunodeficiency virus (HIV) reservoirs by activating resting CD4+ cells. This retrospective case-control study (n = 30) examined effects of VPA on markers of HIV progression. VPA was not associated with changes in cerebrospinal fluid viral loads (VL), plasma VL, or neuropsychological performance. VPA patients had a trend towards lower CD4+ cells (P = .08) at follow-up. Concurrent antiretrovirals did not alter these relationships. VPA does not induce viremia or promote disease progression and may be safe for clinical intervention.

Keywords

CD4+ cell HIV latent virus valproic acid viral load 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Acharya S, Bussel JB (2000). Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 22: 62–65.CrossRefPubMedGoogle Scholar
  2. Carey CL, Woods SP, Rippeth JD, Gonzalez R, Moore DJ, Marcotte TD, Grant I, Heaton RK, Group H (2004). Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clini Neuropsychol 18: 234–248.CrossRefGoogle Scholar
  3. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, McCutchan JA, Reicks C, Grant I, Group H (2004). The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 10: 317–331.CrossRefPubMedGoogle Scholar
  4. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM (2005). Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366: 549–555.CrossRefPubMedGoogle Scholar
  5. Robinson B, Turchan J, Anderson C, Chauhan A, Nath A (2006). Modulation of human immunodeficiency virus infection by anticonvulsant drugs. J NeuroVirol 12: 1–4.CrossRefPubMedGoogle Scholar
  6. Schifitto G, Peterson DR, Zhong J, Ni H, Cruttenden K, Gaugh M, Gendelman HE, Boska M, Gelbard H (2006). Valproic acid adjunctive therapy for HIV-associated cognitive impairment. A first report. Neurology 66: 919–921.CrossRefPubMedGoogle Scholar
  7. Smith SM (2005). Valproic acid and HIV-1 latency: beyond the sound bite. Retrovirology 2: 56.CrossRefPubMedGoogle Scholar
  8. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM (2004). Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 18: 1101–1108.CrossRefPubMedGoogle Scholar

Copyright information

© Journal of NeuroVirology, Inc. 2006

Authors and Affiliations

  • Beau M. Ances
    • 1
    • 4
  • Scott Letendre
    • 2
  • Maria Buzzell
    • 1
  • Jennifer Marquie-Beck
    • 1
  • Deborah Lazaretto
    • 1
  • Thomas D. Marcotte
    • 3
  • Igor Grant
    • 3
  • Ronald J. Ellis
    • 1
  • HNRC Group
  1. 1.Department of NeurosciencesUniversity of CaliforniaSan DiegoUSA
  2. 2.Department of MedicineUniversity of CaliforniaSan DiegoUSA
  3. 3.Department of PsychiatryUniversity of CaliforniaSan DiegoUSA
  4. 4.HIV Neurobehavioral Research CenterSan DiegoUSA

Personalised recommendations